Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 01, 2008. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights as of July 31, 2008, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a capital structure notification.
| Metric | Value |
|---|---|
| Issued Ordinary Shares (25p each) | 5,714,732,135 |
| Treasury Shares | 474,194,158 |
| Total Voting Rights | 5,240,537,977 |
Material Changes
The filing text does not provide comparative data against prior periods to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. Its sole purpose is to inform shareholders of the denominator to be used for calculating disclosure thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,240,537,977) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (474,194,158) to understand the float.
- Note that this filing does not contain operational or financial performance updates.